Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Sales of Investments
Cash received from selling or redeeming investments.
Upstream Bio, Inc.NASDAQ: UPB
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments grows, but more slowly than its trailing trend
Q1 FY2026 sales of investments of $56.82M rose 7.9% year over year, behind the +20.1% change in trailing-twelve-month sales of investments. Sequentially, it fell 41.6% from the prior quarter.
Context
- Sales of investments amounted to 10251.0% of revenue in FY2025, up 477.4 pp from a year earlier.
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +7.9% toward the trailing-twelve-month pace of +20.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 292.56M USD
- Year-over-year change
- +26.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 292.56M | +26.3% |
| FY2024 | 2024-12-31 | 231.64M | +400.4% |
| FY2023 | 2023-12-31 | 46.29M | — |
| FY2022 | 2022-12-31 | 0 | — |
Sales of Investments vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +20.1% is the 4th highest of 8, against a peer median of +2.6%.
- Sales of investments amounts to 8931.7% of revenue for UPB, versus a peer median of 352.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $981.03M USD | +2.6% | +17.3% | 1484.3% | |
| LTM Mar 2026 | $459.13M USD | +22.8% | +16.3% | 211.4% | |
| LTM Mar 2026 | $458.02M USD | -5.9% | — | 76.8% | |
| LTM Sep 2026 | $445.96M USD | +31.2% | +56.7% | 492.8% | |
| LTM Jun 2026 | $369.36M USD | -5.8% | -3.9% | 3568.7% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $296.71M USD | +20.1% | — | 8931.7% |
| LTM Mar 2026 | $296.16M USD | +1470.5% | — | — | |
| LTM Sep 2026 | $228.84M USD | -8.8% | +11.1% | — | |
| LTM Sep 2026 | €0 EUR | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UPB) | — | +2.6% | +16.3% | 352.1% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Depreciation & Amortization | 7K | 60K | 89K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.28M | 3.43M | 6M | 10.33M |
| Change in Working Capital | 3.41M | (4.31M) | 1.87M | 589K |
| Accounts Receivables | (412K) | 314K | (515K) | (55K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 462K | 1.28M | 2.02M | (1.28M) |
| Other Working Capital | 3.36M | (5.9M) | 371K | 1.93M |
| Other Non-Cash Items | 149K | (16.57M) | (4.33M) | 561K |
| Operating Cash Flow | (19.02M) | (37.93M) | (59.17M) | (133.28M) |
| Capital Expenditures | (82K) | (144K) | (511K) | (165K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (128.99M) | (290.61M) | (385.88M) |
| Sales of Investments | 0 | 46.29M | 231.64M | 292.56M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (82K) | (82.84M) | (59.49M) | (93.48M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.96M | 129.55M | 272.72M | 2.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (37K) | 118K | (3.74M) | 0 |
| Financing Cash Flow | 9.96M | 129.55M | 418.91M | 2.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.14M) | 8.78M | 300.25M | (224.31M) |
| Free Cash Flow | (19.1M) | (38.07M) | (59.68M) | (133.28M) |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.